33% REVENUE GROWTH WITH NAMED PATIENT PROGRAM
How the Head of Global Market Access for an oral oncolytic was able to increase revenue potential by thinking outside the U.S.
U.S. manufacturer was launching their first product, an oral oncolytic for a rare sub-indication. Forecast in the U.S. was ~ 500 patients. Challenged to increase revenue potential for the brand.
Archbow consultant recognized the opportunity for a Named Patient Program (NPP) in EU & ROW markets. Identified & vetted a vendor with EU & ROW capabilities.
Established protocol to import product, sell in ex-U.S. markets, collect & report AEs consistently, and communicate with HCPs.
By end of year 1, 1/3 of all product sales occurring outside of U.S. Distribution eventually expanded to multiple markets, including EU, Asia, & South America. All NPP sales counted toward U.S. revenue (top line).
Leveraged market & HCP knowledge to ensure smooth transitions to commercial operations as product was approved in ex-U.S. markets.